Attovia Therapeutics, Inc. (ATTO) Stock Forecast
ATTO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $42.20 average of analyst targets
- Upside to target
- +207.4% from the latest close
- Next earnings
- December 2, 2026 EPS estimate $-0.74
- 52-week range
- $13.73 – $25.55
ATTO analyst ratings
5 analystsNumber of analysts at each rating.
ATTO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATTO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.50 | −$0.50 | −$0.50 | — | — | 1 |
| Current fiscal year (2026) | −$3.45 | −$3.45 | −$3.45 | — | — | 1 |
| Next fiscal year (2027) | −$2.38 | −$2.38 | −$2.38 | −$3.45 | +31.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ATTO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 2 |
| Current fiscal year (2026) | $466,670 | $450,000 | $500,000 | — | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | −100.0% | 4 |
ATTO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ATTO revenue: reported and forecast
ATTO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | $0.00 | −$0.50 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | −$3.45 | — | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$2.38 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ATTO earnings surprises
Reported EPS vs the consensus estimate for the last 1 quarters; ATTO beat in 0 of 1.
What analysts expect from ATTO
5 analysts cover Attovia Therapeutics; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $42.20, 207.4% above the latest close of $13.73. Analysts expect earnings of −$3.45 per share for 2026. For 2027 the average estimate is −$2.38 per share. Attovia Therapeutics beat the EPS estimate in 0 of the last 1 quarters.
Related: ATTO income statement, ATTO key metrics, ATTO chart. See the ATTO stock overview for the latest quote and news.
ATTO forecast FAQ
What is Attovia Therapeutics's price target?
The average analyst price target for Attovia Therapeutics is $42.20, 207.4% above the latest close of $13.73.
Is Attovia Therapeutics a buy, hold or sell?
Of 5 analysts covering Attovia Therapeutics, 3 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Attovia Therapeutics's EPS forecast?
Analysts forecast −$3.45 per share for 2026 (range −$3.45 to −$3.45); for 2027 the estimate is −$2.38.
What is Attovia Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.5 million.
When does Attovia Therapeutics report earnings?
Attovia Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 2, 2026; the EPS estimate is $-0.74.
Does Attovia Therapeutics usually beat earnings estimates?
Attovia Therapeutics reported EPS at or above the analyst estimate in 0 of the last 1 quarters.